Shares surged 9.4% to $135.59 as Insmed locked in the final piece of its global regulatory trifecta. Japan's Ministry of Health, Labour and Welfare on August 24 approved Brinsupri — a once-daily pill for bronchiectasis, a chronic lung disease that causes permanent airway damage — making it the first and only approved therapy for the condition in Japan.

Brinsupri is now cleared in the U.S., Europe, and Japan. Mizuho promptly nudged its price target higher. The question now: how fast can Japan move the revenue needle on a drug already growing faster than anyone expected?

  • Japan Was the Missing Market — And It's Bigger Than It Looks

Roughly 9% of the world's roughly one million diagnosed non-cystic fibrosis bronchiectasis patients live in Japan , and the country's market for the condition accounted for nearly 25% of total revenue across the seven major markets.

Because Brinsupri is the first and only approved treatment there , Insmed faces zero direct competition at launch — a rare luxury. Management previously told analysts it expected meaningful international revenue from Japan beginning in 2027.

  • The U.S. Launch Already Shattered Expectations

Brinsupri generated $309.2 million in second-quarter revenue, a 49% sequential jump that prompted Insmed to raise its full-year 2026 guidance to $1.25–$1.40 billion — up from a prior outlook of over $1 billion.

The company also boosted its combined peak sales estimate for its three lead drugs by 75% to more than $14 billion , with Brinsupri alone now expected to exceed $7 billion at peak. Japan adds a large, untapped patient population to that runway.

  • Mizuho's Target Bump Is Modest — Read Between the Lines

Analyst Graig Suvannavejh raised his price target to $195 from $192 while keeping an Outperform rating. That $3 increase on a drug just cleared in a major new market signals the Japan opportunity was largely baked into models. Mizuho said recent share weakness was "unwarranted" and that management has been "quite bullish" on Japan.

The Wall Street consensus target sits near $205.52 , suggesting analysts collectively still see roughly 50% upside.

  • Profitability Is Within Reach — If Spending Stays Disciplined

Insmed's net loss narrowed sharply to $13.2 million in Q2 from $321.7 million a year earlier , and the company maintains $1.2 billion in cash and expects to reach cash-flow-positive status in 2027 without raising new capital. Japan's launch costs could pressure margins short-term, but Brinsupri's low manufacturing costs relative to Insmed's older inhaled drug should help offset them.

The approval eliminates regulatory risk in the world's third-largest pharmaceutical market. For shareholders, the real test is execution: converting Japan's unmet need into prescriptions as efficiently as the U.S. launch has delivered.